Generic Verkazia Availability
Last updated on Apr 10, 2025.
Verkazia is a brand name of cyclosporine ophthalmic, approved by the FDA in the following formulation(s):
VERKAZIA (cyclosporine - emulsion;ophthalmic)
-
Manufacturer: HARROW EYE
Approval date: June 23, 2021
Strength(s): 0.1% [RLD]
Is there a generic version of Verkazia available?
No. There is currently no therapeutically equivalent version of Verkazia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Verkazia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same
Patent 11,612,658
Issued: March 28, 2023
Inventor(s): Rabinovich-Guilatt; Laura et al.
Assignee(s): SANTEN SAS (Evry, FR)Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
Patent expiration dates:
- January 27, 2026✓
- January 27, 2026
-
Emulsion compositions containing quaternary ammonium compounds
Patent 7,973,081
Issued: July 5, 2011
Inventor(s): Rabinovich-Guilatti; Laura et al.
Assignee(s): Novagali Pharma SA (Evry, FR)Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
Patent expiration dates:
- January 27, 2026✓
- January 27, 2026
-
Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Patent 8,298,568
Issued: October 30, 2012
Inventor(s): Bague Séverine & Philips Betty & Garrigue Jean-Sébastien & Rabinovich-Guilatt Laura & Lambert Gregory
Assignee(s): Novagali Pharma SAA well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.
Patent expiration dates:
- November 3, 2027✓
- November 3, 2027
-
Emulsion compositions containing quaternary ammonium compounds
Patent 8,524,779
Issued: September 3, 2013
Inventor(s): Rabinovich-Guilatti Laura & Lambert Gregory & Lallemand Frederic & Philips Betty
Assignee(s): Novagali Pharma SAComposition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
Patent expiration dates:
- January 27, 2026✓
- January 27, 2026
-
Compositions containing quaternary ammonium compounds
Patent 9,132,071
Issued: September 15, 2015
Inventor(s): Rabinovich-Guilatt Laura & Lambert Gregory & Lallemand Frederic & Philips Betty
Assignee(s): SANTEN SASCompositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, where composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, and the ophthalmic emulsions being are useful for eye care or for the treatment of eye conditions.
Patent expiration dates:
- June 2, 2029✓
- June 2, 2029
-
Emulsion compositions containing cetalkonium chloride
Patent 9,220,694
Issued: December 29, 2015
Inventor(s): Rabinovich-Guilatt Laura & Lambert Gregory & Lallemand Frederic & Philips Betty
Assignee(s): SANTEN SASCompositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
Patent expiration dates:
- January 27, 2026✓
- January 27, 2026
-
Emulsion compositions containing quaternary ammonium compounds
Patent 9,956,289
Issued: May 1, 2018
Inventor(s): Rabinovich-Guilatt Laura & Lambert Gregory & Lallemand Frederic & Philips Betty
Assignee(s): SANTEN SASCompositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
Patent expiration dates:
- January 27, 2026✓
- January 27, 2026
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 23, 2028 - FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS
More about Verkazia (cyclosporine ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous ophthalmic agents
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
